Le Lézard
Classified in: Health, Business
Subjects: JVN, TRI

HFSA Partners With XpertDox To Leverage XpertTrial, A Clinical Trial Recruitment Platform, To Accelerate Medical Research


ROCKVILLE, Md. and BIRMINGHAM, Ala., Sept. 6, 2018 /PRNewswire/ -- The Heart Failure Society of America (HFSA) and XpertDox today announced a partnership to leverage the XpertDox product, XpertTrialTM, a clinical trial search and engagement platform. The XpertTrial platform will provide patients and providers with the most up-to-date information regarding actively-recruiting, U.S.-based heart failure related clinical trials (https://www.xpertdox.com/hfsa/).

Heart Failure Society of America and XpertDox

"This important initiative builds on our efforts to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy," commented Dr. Christopher O'Connor, MD, FHFSA, President of The Heart Failure Society of America.  "We are pleased to partner with XpertDox and are excited to leverage their XpertTrial platform to promote current heart failure clinical trials; provide a centralized location for heart failure patients; caregivers; and providers to engage with on-going clinical trials and; increase understanding of available heart failure clinical trials and recruitment criteria."

Dr. Sameer Ather, MD, PhD, CEO and co-founder of XpertDox commented, "The XpertTrial Platform has been designed specifically to accelerate access to clinical trial data and provide the information necessary to make informed decisions. This collaboration will enable users to easily search for information, identify clinical trial opportunities and access the latest heart failure research."  Dr. Ather continued, "HFSA adds tremendous value to heart failure specialists, patients and caregivers and we are proud to partner with them."

XpertTrial is a natural language processing search engine that can match more than 70,000 keywords to all actively recruiting clinical trials across all diseases, procedures, symptoms, and specialties. This powerful clinical trial search engine harnesses a proprietary algorithm that leverages big data to generate network mapping between diseases, procedures and clinical trials. 

About The Heart Failure Society of America
The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart failure, research and patient care. 

About XpertDox
XpertDox is dedicated to improving healthcare outcomes for patients with rare and serious conditions. XpertDox leverages its proprietary products, XpertTrial, XpertMatch, and XpertKOL, to aid healthcare organizations, institutions, and leaders in the industry to find patients, clinical trials, and key opinion leaders for over 6,000 diseases.  For additional information visit www.XpertDox.com.

CONTACT
Sameer Ather, XpertDox
[email protected] 205-259-6045

 

SOURCE Heart Failure Society of America


These press releases may also interest you

at 08:17
On April 25, 2024, the Board of Directors of Woodlands Financial Services Company declared a quarterly cash dividend of twenty-nine cents per share on its common stock, payable on May 24, 2024, to shareholders of record as of May 10, 2024. ...

at 08:14
Trading resumes in: Company: Medicenna Therapeutics Corp. TSX Symbol: MDNA All Issues: Yes Resumption (ET): 8:30 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts...

at 08:09
Adyton Resources Corporation announces that it has filed its financial statements for the three and twelve months ended December 31, 2023 and accompanying Management Discussion and Analysis on its SEDAR profile at www.sedar.com. ...

at 08:07
The following issues have been halted by CIRO: Company: Medicenna Therapeutics Corp. TSX Symbol: MDNA All Issues: Yes Reason: Pending News Halt Time (ET): 8:00 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a...

at 08:05
Cutera, Inc. ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, today announced that it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 9, 2024....

at 08:05
The Beauty Health Company , home to flagship brand Hydrafacialtm, today announced it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. The Company will host an investor conference call at 4:30 p.m. Eastern...



News published on and distributed by: